LSTA - Lisata Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

LSTA

LISATA THERAPEUTICS, INC.

NASDAQ

$1.69

▼ DOWN 7.14% (-0.13)

KEY STATISTICS

Market Cap$15.39 M

52w High$5.07

52w Low$0.99

Dividend Yield0.03%

FrequencySpecial

P/E-1.03

Volume244.92K

Shares Out.9.11M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

David J. Mazzo

COMPENSATION 2026

Salary$702,969

Stock Awards$468,160

Incentive Plan Pay$0

All Other Comp.$30,250

Total$1,691,174

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 1, 1999

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2022-09-15	Reverse	1:15
2016-07-28	Reverse	1:10
2013-07-16	Reverse	1:10
2007-08-09	Reverse	1:10
2006-08-31	Reverse	1:10

PRICE

$1.69 ▼ DOWN 7.14% (−$0.13)

OVERLAYS

About Lisata Therapeutics, Inc.

https://www.lisata.com ↗

Lisata Therapeutics, Inc. is a clinical-stage biopharma developing cellular therapies like HONEDRA, XOWNA, and CLBS201 to treat conditions such as critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease.

INDUSTRY

Biotechnology

A PRODUCT LISATA THERAPEUTICS, INC. IS KNOWN FOR

Certepetide

Certepetide, Lisata's lead investigational drug from the CendR Platform®, aims to improve anti-cancer therapy delivery to solid tumors and is currently in clinical trials for advanced cancers like pancreatic cancer.